The Company’s common stock will continue to trade under stock symbol “CTIX” on OTCQB until market close on June 8, 2017. Trading on the OTCQB under the new Innovation Pharmaceuticals name and ticker symbol “IPIX” will begin at market open on June 9, 2017. The Company’s new website address will change to www.IPharmInc.com. In the interim, the Company will maintain www.cellceutix.com. Will need to update the name for the thread and stock symbol as well.
Thursday conference for kevetrin. http://www.cellceutix.com/new-event...ean-hematology-association-eha-annual-meeting
Innovation Pharmaceuticals Inc., (otcqb:IPIX), a clinical stage biopharmaceutical company, is pleased to announce highly encouraging preliminary data from the first patients treated in the Company's Phase 2a clinical trial of Kevetrin for ovarian cancer: https://www.marketwatch.com/story/i...kevetrin-ph2a-ovarian-cancer-trial-2017-12-27
The only thing that will get this company out of the gutter is partnership news. Hopefully 2018 brings that. They have some very promising drug candidates in mid-late stage trials and a solid trial history. I'm hopeful, but years of stagnant or declining SP has been disheartening. I first invested in CTIX when I was a new investor. Knowing what I know now, I would not have at the time. I said the word 'hope' a lot, that tells you all you need to know about CTIX/IPIX as an investment.
Yesterday, the company provided additional perspectives on the planned continued development of Brilacidin-OM for the prevention and treatment of Oral Mucositis (OM) in Head and Neck Cancer (HNC) patients. The Phase 2 randomized, placebo-controlled clinical trial of Brilacidin-OM, enrolling a total of 61 patients, recently was completed,.
